Home » Stocks » Intellipharmaceutics International

Intellipharmaceutics International Inc. (IPCIF)

Stock Price: $0.140 USD 0.000 (-0.07%)
Updated Aug 14, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 3.31M
Revenue (ttm) 2.70M
Net Income (ttm) -8.08M
Shares Out 23.68M
EPS (ttm) -0.24
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 14, 2020
Last Price $0.140
Previous Close $0.140
Change ($) 0.000
Change (%) -0.07%
Day's Open 0.143
Day's Range 0.139 - 0.143
Day's Volume 2,500
52-Week Range 0.125 - 0.172

More Stats

Market Cap 3.31M
Enterprise Value 5.15M
Earnings Date (est) Oct 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 23.68M
Float 23.06M
EPS (basic) -0.37
EPS (diluted) -0.24
FCF / Share -0.31
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 713,995
Short Ratio 0.39
Short % of Float 3.35%
Beta 1.62
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.23
PB Ratio n/a
Revenue 2.70M
Operating Income -7.83M
Net Income -8.08M
Free Cash Flow -6.68M
Net Cash -1.84M
Net Cash / Share -0.08
Gross Margin 127.88%
Operating Margin -290.64%
Profit Margin -232.30%
FCF Margin -247.73%
ROA -64.67%
ROE -3,942.90%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$25.00*
Low
25.0
Current: $0.140
High
25.0
Target: 25.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue3.481.715.502.254.098.771.530.110.501.46
Revenue Growth103.21%-68.88%144.97%-45.11%-53.32%474.13%1326.33%-78.66%-65.61%-
Gross Profit3.451.594.802.254.098.771.530.110.501.46
Operating Income-7.83-13.33-8.27-9.85-7.11-3.53-6.82-10.12-7.78-6.05
Net Income-8.08-13.75-8.86-10.14-7.44-3.86-11.50-6.14-4.88-5.76
Shares Outstanding21.584.763.102.672.382.311.971.731.501.09
Earnings Per Share-0.37-2.89-2.86-3.80-3.10-1.70-5.80-3.60-3.30-5.30
Operating Cash Flow-6.66-12.51-6.11-6.25-3.78-1.71-6.93-7.65-6.98-6.19
Capital Expenditures-0.01-0.10-1.82-0.52-0.43-0.77-0.12-1.04-0.26-0.13
Free Cash Flow-6.68-12.61-7.93-6.77-4.21-2.48-7.05-8.69-7.24-6.33
Cash & Equivalents0.066.641.904.141.764.230.760.504.820.79
Total Debt1.901.791.291.511.551.442.150.100.140.01
Net Cash / Debt-1.844.850.612.630.202.79-1.390.404.680.78
Assets3.8011.477.407.975.227.884.382.476.253.27
Liabilities7.497.377.016.865.362.9710.334.249.343.17
Book Value-3.694.100.391.12-0.144.91-5.96-1.77-3.090.09
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Intellipharmaceutics International Inc.
Country Canada
Employees 33
CEO Isa Odidi

Stock Information

Ticker Symbol IPCIF
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: IPCIF

Description

Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; and Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression. It also provides Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Pristiq, a desvenlafaxine extended-release tablet to treat depression; and Regabatin and Lyrica, a pregabalin extended-release capsule for the management of neuropathic pain. In addition, the company offers Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Oleptro, a trazodone hydrochloride extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, it is developing Oxycodone ER, an extended release tablet for relief of pain. The company has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.